The Experts below are selected from a list of 55368 Experts worldwide ranked by ideXlab platform
Alasdair J. Nisbet - One of the best experts on this subject based on the ideXlab platform.
-
field evaluation of poultry red mite dermanyssus gallinae native and Recombinant prototype vaccines
Veterinary Parasitology, 2017Co-Authors: Kathryn Bartley, F. Turnbull, H. W. Wright, J. F. Huntley, Mintu Nath, Javier Palareaalbaladejo, Alasdair J. NisbetAbstract:Vaccination is a desirable emerging strategy to combat poultry red mite (PRM), Dermanyssus gallinae. We performed trials, in laying hens in a commercial-style cage facility, to test the vaccine efficacy of a native preparation of soluble mite extract (SME) and of a Recombinant Antigen cocktail vaccine containing bacterially-expressed versions of the immunogenic SME proteins Deg-SRP-1, Deg-VIT-1 and Deg-PUF-1. Hens (n = 384 per group) were injected with either vaccine or adjuvant only (control group) at 12 and 17 weeks of age and then challenged with PRM 10 days later. PRM counts were monitored and, at the termination of the challenge period (17 weeks post challenge), average PRM counts in cages containing birds vaccinated with SME were reduced by 78% (p < 0.001), compared with those in the adjuvant-only control group. When the trial was repeated using the Recombinant Antigen cocktail vaccine, no statistically significant differences in mean PRM numbers were observed in cages containing vaccinated or adjuvant-only immunised birds. The roles of Antigen-specific antibody levels and duration in providing vaccine-induced and exposure-related protective immunity are discussed.
-
Field evaluation of poultry red mite (Dermanyssus gallinae) native and Recombinant prototype vaccines
2017Co-Authors: Kathryn Bartley, F. Turnbull, H. W. Wright, J. F. Huntley, Javier Palarea-albaladejo, Mintu Nath, Alasdair J. NisbetAbstract:Vaccination is a desirable emerging strategy to combat poultry red mite (PRM), Dermanyssus gallinae. We performed trials, in laying hens in a commercial-style cage facility, to test the vaccine efficacy of a native preparation of soluble mite extract (SME) and of a Recombinant Antigen cocktail vaccine containing bacterially-expressed versions of the immunogenic SME proteins Deg-SRP-1, Deg-VIT-1 and Deg-PUF-1. Hens (n=384 per group) were injected with either vaccine or adjuvant only (control group) at 12 and 17 weeks of age and then challenged with PRM 10days later. PRM counts were monitored and, at the termination of the challenge period (17 weeks post challenge), average PRM counts in cages containing birds vaccinated with SME were reduced by 78% (p
Olli Vapalahti - One of the best experts on this subject based on the ideXlab platform.
-
validation of an automated elisa system for detection of antibodies to aleutian mink disease virus using blood samples collected in filter paper strips
Virology Journal, 2014Co-Authors: Anna Knuuttila, Pirjo Aronen, Majvor Eerola, Ian A Gardner, Annamaija Virtala, Olli VapalahtiAbstract:Background Aleutian mink disease virus (AMDV) is the cause of a chronic immune complex disease, Aleutian disease (AD), which is common in mink-producing countries. In 2005, implementation of an AMDV eradication programme in Finland created a need for an automated high-throughput assay. The aim of this study was to validate an AMDV-VP2 -Recombinant Antigen ELISA, which we developed earlier, in an automated assay format for the detection of anti-AMDV antibodies in mink blood and to determine the accuracy of this test compared with the reference standard (counter-current immunoelectrophoresis, CIEP).
-
development and evaluation of an enzyme linked immunosorbent assay based on Recombinant vp2 capsids for the detection of antibodies to aleutian mink disease virus
Clinical and Vaccine Immunology, 2009Co-Authors: Anna Knuuttila, Pirjo Aronen, Auli Saarinen, Olli VapalahtiAbstract:Aleutian disease (AD), a common infectious disease in farmed minks worldwide, is caused by Aleutian mink disease virus (AMDV). Serodiagnosis of AD in minks has been based on detection of AMDV antibodies by counterimmunoelectrophoresis (CIE) since the 1980s. The aim of this study was to develop and evaluate an enzyme-linked immunosorbent assay (ELISA) based on Recombinant virus-like particles (VLPs) for identifying AMDV antibodies from mink sera. AMDV capsid protein (VP2) of a Finnish wild-type strain was expressed by the baculovirus system in Spodoptera frugiperda 9 insect cells and was shown to self-assemble to VLPs (with an ultrastructure similar to that of the actual virion). A direct immunoglobulin G ELISA was established using purified Recombinant AMDV VP2 VLPs as an Antigen. Sera from farmed minks were collected to evaluate the AMDV VP2 ELISA (n = 316) and CIE (n = 209) based on AMDV VP2 Recombinant Antigen in parallel with CIE performed using a commercially available traditional Antigen. CIE performed with the Recombinant Antigen had a sensitivity and specificity of 100% and ELISA a sensitivity of 99% and a specificity of 97%, with reference to CIE performed with the commercial Antigen. The results show that the Recombinant AMDV VP2 VLPs are Antigenic and that AMDV VP2 ELISA is sensitive and specific and encourage further development of the method for high-throughput diagnostics, involving hundreds of thousands of samples in Finland annually.
Kathryn Bartley - One of the best experts on this subject based on the ideXlab platform.
-
field evaluation of poultry red mite dermanyssus gallinae native and Recombinant prototype vaccines
Veterinary Parasitology, 2017Co-Authors: Kathryn Bartley, F. Turnbull, H. W. Wright, J. F. Huntley, Mintu Nath, Javier Palareaalbaladejo, Alasdair J. NisbetAbstract:Vaccination is a desirable emerging strategy to combat poultry red mite (PRM), Dermanyssus gallinae. We performed trials, in laying hens in a commercial-style cage facility, to test the vaccine efficacy of a native preparation of soluble mite extract (SME) and of a Recombinant Antigen cocktail vaccine containing bacterially-expressed versions of the immunogenic SME proteins Deg-SRP-1, Deg-VIT-1 and Deg-PUF-1. Hens (n = 384 per group) were injected with either vaccine or adjuvant only (control group) at 12 and 17 weeks of age and then challenged with PRM 10 days later. PRM counts were monitored and, at the termination of the challenge period (17 weeks post challenge), average PRM counts in cages containing birds vaccinated with SME were reduced by 78% (p < 0.001), compared with those in the adjuvant-only control group. When the trial was repeated using the Recombinant Antigen cocktail vaccine, no statistically significant differences in mean PRM numbers were observed in cages containing vaccinated or adjuvant-only immunised birds. The roles of Antigen-specific antibody levels and duration in providing vaccine-induced and exposure-related protective immunity are discussed.
-
Field evaluation of poultry red mite (Dermanyssus gallinae) native and Recombinant prototype vaccines
2017Co-Authors: Kathryn Bartley, F. Turnbull, H. W. Wright, J. F. Huntley, Javier Palarea-albaladejo, Mintu Nath, Alasdair J. NisbetAbstract:Vaccination is a desirable emerging strategy to combat poultry red mite (PRM), Dermanyssus gallinae. We performed trials, in laying hens in a commercial-style cage facility, to test the vaccine efficacy of a native preparation of soluble mite extract (SME) and of a Recombinant Antigen cocktail vaccine containing bacterially-expressed versions of the immunogenic SME proteins Deg-SRP-1, Deg-VIT-1 and Deg-PUF-1. Hens (n=384 per group) were injected with either vaccine or adjuvant only (control group) at 12 and 17 weeks of age and then challenged with PRM 10days later. PRM counts were monitored and, at the termination of the challenge period (17 weeks post challenge), average PRM counts in cages containing birds vaccinated with SME were reduced by 78% (p
Anna Knuuttila - One of the best experts on this subject based on the ideXlab platform.
-
validation of an automated elisa system for detection of antibodies to aleutian mink disease virus using blood samples collected in filter paper strips
Virology Journal, 2014Co-Authors: Anna Knuuttila, Pirjo Aronen, Majvor Eerola, Ian A Gardner, Annamaija Virtala, Olli VapalahtiAbstract:Background Aleutian mink disease virus (AMDV) is the cause of a chronic immune complex disease, Aleutian disease (AD), which is common in mink-producing countries. In 2005, implementation of an AMDV eradication programme in Finland created a need for an automated high-throughput assay. The aim of this study was to validate an AMDV-VP2 -Recombinant Antigen ELISA, which we developed earlier, in an automated assay format for the detection of anti-AMDV antibodies in mink blood and to determine the accuracy of this test compared with the reference standard (counter-current immunoelectrophoresis, CIEP).
-
development and evaluation of an enzyme linked immunosorbent assay based on Recombinant vp2 capsids for the detection of antibodies to aleutian mink disease virus
Clinical and Vaccine Immunology, 2009Co-Authors: Anna Knuuttila, Pirjo Aronen, Auli Saarinen, Olli VapalahtiAbstract:Aleutian disease (AD), a common infectious disease in farmed minks worldwide, is caused by Aleutian mink disease virus (AMDV). Serodiagnosis of AD in minks has been based on detection of AMDV antibodies by counterimmunoelectrophoresis (CIE) since the 1980s. The aim of this study was to develop and evaluate an enzyme-linked immunosorbent assay (ELISA) based on Recombinant virus-like particles (VLPs) for identifying AMDV antibodies from mink sera. AMDV capsid protein (VP2) of a Finnish wild-type strain was expressed by the baculovirus system in Spodoptera frugiperda 9 insect cells and was shown to self-assemble to VLPs (with an ultrastructure similar to that of the actual virion). A direct immunoglobulin G ELISA was established using purified Recombinant AMDV VP2 VLPs as an Antigen. Sera from farmed minks were collected to evaluate the AMDV VP2 ELISA (n = 316) and CIE (n = 209) based on AMDV VP2 Recombinant Antigen in parallel with CIE performed using a commercially available traditional Antigen. CIE performed with the Recombinant Antigen had a sensitivity and specificity of 100% and ELISA a sensitivity of 99% and a specificity of 97%, with reference to CIE performed with the commercial Antigen. The results show that the Recombinant AMDV VP2 VLPs are Antigenic and that AMDV VP2 ELISA is sensitive and specific and encourage further development of the method for high-throughput diagnostics, involving hundreds of thousands of samples in Finland annually.
Julien Muzard - One of the best experts on this subject based on the ideXlab platform.
-
creation of Recombinant Antigen binding molecules derived from hybridomas secreting specific antibodies
Nature Protocols, 2013Co-Authors: Conor Fields, David J Oconnell, Sujing Xiao, Philippe Billiald, Julien MuzardAbstract:Creation of Recombinant Antigen-binding molecules derived from hybridomas secreting specific antibodies
-
Creation of Recombinant Antigen-binding molecules derived from hybridomas secreting specific antibodies
Nature Protocols, 2013Co-Authors: Conor Fields, Sujing Xiao, Philippe Billiald, David O'connell, Julien MuzardAbstract:This protocol describes the design and development of Recombinant monovalent Antigen-binding molecules derived from monoclonal antibodies through rapid identification and cloning of the functional variable heavy ( VH ) and variable light ( VL ) genes and the design and cloning of a synthetic DNA sequence optimized for expression in Recombinant bacteria. Typically, monoclonal antibodies are obtained from mouse hybridomas, which most often result from the fusion of B lymphocytes from immunized mice with murine myeloma cells. The protocol described here has previously been exploited for the successful development of multiple antibody-based molecules targeting a wide range of biomolecular targets. The protocol is accessible for research groups who may not be specialized in this area, and should permit the straightforward reverse engineering of functional, Recombinant Antigen-binding molecules from hybridoma cells secreting functional IgGs within 50 working days. Furthermore, convenient strategies for purification of antibody fragments are described.